REFRACTORY RENAL CELL CARCINOMA
Clinical trials for REFRACTORY RENAL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY RENAL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for REFRACTORY RENAL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Two-Drug combo aims to starve and attack advanced cancers
Disease control OngoingThis early-phase trial tests the safety and best dose of combining two drugs—ziv-aflibercept and pembrolizumab—in people with advanced solid tumors that have spread. Ziv-aflibercept cuts off the tumor's blood supply, while pembrolizumab helps the immune system fight cancer. The s…
Matched conditions: REFRACTORY RENAL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 05:58 UTC
-
New hope for kids with rare cancers: drug blocks tumor growth
Disease control OngoingThis study tests a daily pill called cabozantinib in children and young adults (up to age 30) with rare cancers like sarcomas, Wilms tumor, and others that have come back or not responded to treatment. The drug works by blocking signals that help tumors grow and form blood vessel…
Matched conditions: REFRACTORY RENAL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:37 UTC